BioMarin Pharmaceutical vs Neurocrine Biosciences
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put BioMarin Pharmaceutical and Neurocrine Biosciences side by side, using each one’s latest annual report. Here is what stands out:
- BioMarin Pharmaceutical is the larger business, with $3.2B of revenue in fiscal 2025 against $2.9B for Neurocrine Biosciences.
- Neurocrine Biosciences grew revenue faster (21.5%, against 12.9%).
- Neurocrine Biosciences kept more of each dollar of sales as operating profit (21.6% operating margin, against 12.7%).
- Neurocrine Biosciences turned more of its sales into free cash flow (26.2% FCF margin, against 22.5%).
- Neurocrine Biosciences earned a higher return on the capital invested in it (25.6%, against 5.8%).
- Investors pay more for each dollar of BioMarin Pharmaceutical’s earnings: a P/E of 150.7x against 21.4x for Neurocrine Biosciences.
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
BioMarin Pharmaceutical
BMRN
0/11
Neurocrine Biosciences
NBIX
11/11
Revenue growth5-year growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | BMRN FY25 | NBIX FY25 |
|---|---|---|
| Size | ||
| Market cap | $10.8B | $15.2B |
| Revenue | $3.2B | $2.9B |
| Free cash flow | $725M | $749M |
| Net income | $349M | $479M |
| Growth | ||
| Revenue growth | 12.9% | 21.5% |
| 5-year growth | 11.6% | 22.3% |
| Share count change | 0.4% | −1.2% |
| Profitability | ||
| Gross margin | 77.7% | 98.2% |
| Operating margin | 12.7% | 21.6% |
| Net margin | 10.8% | 16.7% |
| FCF margin | 22.5% | 26.2% |
| Return on capital | 5.8% | 25.6% |
| Return on equity | 5.9% | 16.4% |
| Balance sheet | ||
| Net debt | −$963M | −$1.5B |
| Net debt / EBITDA | −2.0x | −2.3x |
| Dividends and buybacks | $0.0M | $168M |
| Valuation & quality | ||
| P/E | 150.7x | 21.4x |
| Piotroski F-score | 5 | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.